Literature DB >> 23154228

What have we learned about the treatment of type 2 diabetes? The evolving paradigms.

Jeffrey S Freeman1, Edward S Horton.   

Abstract

Insulin, the first treatment for diabetes, was discovered >90 years ago. Since then, many new types of insulin have become available, including analogs that more closely mimic the characteristics of endogenous insulin. In addition, oral antidiabetes drugs and other types of injectable therapies have been approved for the treatment of patients with type 2 diabetes. As newer treatments are approved for type 2 diabetes, the choice and-paradoxically-the complexity of treatment increases. The potential benefits of all treatment options must be carefully balanced against potential adverse events to truly analyze the overall efficacy, safety, tolerability, and potential long-term effects. The manner in which outcomes are assessed and the methods employed to make such assessments have changed over time. This review will address these issues as they are related to therapies for type 2 diabetes, including insulin, oral antidiabetes drugs, and incretin-based agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154228     DOI: 10.1097/MJT.0b013e31826fc5e5

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  1 in total

1.  Effects of metformin and sitagliptin on glycolipid metabolism in type 2 diabetic rats on different diets.

Authors:  Juhong Yang; Tu Ba; Liming Chen; Chunyan Shan; Miaoyan Zheng; Ying Wang; Huizhu Ren; Jingli Chen; Jie Xu; Fei Han; Yi Zhang; Xiaoyun Yang; Baocheng Chang
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.